JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma

  • 0Department of Gastroenterology, Nara Medical University, Nara, Japan.
Anticancer Research +

|

September 26, 2025

|

September 26, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Intestinal permeability (IP) and serum soluble CD163 (sCD163) predict response to atezolizumab plus bevacizumab (Atez/Bev) in advanced hepatocellular carcinoma (aHCC). Lower IP and sCD163 levels correlate with better treatment outcomes and survival.

Area Of Science

  • Oncology
  • Immunotherapy
  • Hepatocellular Carcinoma Research

Background

  • Advanced hepatocellular carcinoma (aHCC) presents challenges for predicting treatment efficacy.
  • Atezolizumab plus bevacizumab (Atez/Bev) is a key treatment, but response predictors are needed.

Purpose Of The Study

  • To identify predictors of therapeutic response to Atez/Bev in aHCC patients.
  • To evaluate the role of intestinal permeability (IP) and specific biomarkers in treatment outcomes.

Main Methods

  • Assessed IP using lactulose-to-mannitol ratio (LMR) in 28 of 39 aHCC patients.
  • Measured serum soluble CD163 (sCD163) and soluble mannose receptor (sMR).
  • Correlated IP markers with objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

Main Results

  • Higher LMR, sCD163, and sMR were associated with progressive disease.
  • Low LMR and low sCD163 levels predicted longer PFS and OS.
  • sCD163 was significantly associated with DCR (OR=14.3, p=0.022).

Conclusions

  • Intestinal permeability is linked to Atez/Bev response in aHCC.
  • Serum sCD163 shows potential as a predictive biomarker for Atez/Bev therapy in aHCC.

Keywords: